Literature DB >> 10981749

Adult medulloblastoma: prognostic factors and patterns of relapse.

A W Chan1, N J Tarbell, P M Black, D N Louis, M P Frosch, M Ancukiewicz, P Chapman, J S Loeffler.   

Abstract

OBJECTIVE: To determine the patterns of relapse and the prognostic factors for adult medulloblastomas treated in the magnetic resonance imaging era.
METHODS: Between 1986 and 1996, 32 adult patients (age, > or =16 yr) with medulloblastomas confined to the craniospinal axis were treated in our institutions. Twenty cases involved classic histological features and 12 involved the desmoplastic variant. The Chang staging distribution was as follows: T1, 2; T2, 17; T3, 10; T4, 3; M0, 24; M1, 1; M2, 4; M3, 3. Brainstem invasion was present in nine patients. Lesions were midline in 13 cases and lateral in 19. Resection was complete in 17 cases, subtotal in 6, and partial in 5, with biopsy only in 4 cases. All patients received postoperative radiotherapy, with median doses of 36 Gy to the entire craniospinal axis and 55 Gy to the posterior fossa. Twenty-four patients received chemotherapy (20 before radiotherapy, 3 after radiotherapy, and 1 before and after radiotherapy).
RESULTS: With a median follow-up period of 5.4 years, 17 patients experienced recurrences. At 5 and 8 years, overall survival rates were 83 and 45% and disease-free survival rates were 57 and 40%, respectively. The 5- and 8-year posterior fossa control rates were 67 and 59%, respectively. Twenty-nine percent of all relapses occurred more than 5 years after treatment. The posterior fossa was the most common site of relapses. In univariate analyses, factors adversely affecting posterior fossa control were less than complete resection (P<0.001), the presence of brainstem invasion (P = 0.02), and the use of chemotherapy (P = 0.03). The overall radiotherapy duration was marginally significant in predicting posterior fossa control, with 5-year posterior fossa control rates of 81 and 49% for durations of less than 48 days and 48 days or more, respectively (P = 0.06). In a multivariate analysis, complete resection was predictive of improved posterior fossa control (P = 0.02) and disease-free survival (P = 0.02) rates. Of the eight low-risk patients who received radiotherapy alone, three experienced recurrences in the bone as the only site of relapse.
CONCLUSION: Late relapse is common among adult patients with medulloblastomas, and long-term follow-up monitoring is important. Because of the high risk of systemic failure among the low-risk patients treated with radiotherapy alone, the role of chemotherapy for this group of patients needs to be further investigated. Complete resection, the absence of brainstem invasion, and an overall radiotherapy duration of less than 48 days are important prognostic factors.

Entities:  

Mesh:

Year:  2000        PMID: 10981749     DOI: 10.1097/00006123-200009000-00018

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  56 in total

Review 1.  Medulloblastoma: therapy and biologic considerations.

Authors:  Timothy R Gershon; Orren J Becher
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Postoperative radiation therapy for medulloblastoma--high recurrence rate in the subfrontal region.

Authors:  Li-Min Sun; Shyh-An Yeh; Chong-Jong Wang; Eng-Yen Huang; Hui-Chun Chen; Hsuan-Chih Hsu; Steve P Lee
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

3.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

4.  Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse.

Authors:  Ulrich Herrlinger; A Steinbrecher; J Rieger; P Hau; R-D Kortmann; R Meyermann; M Schabet; M Bamberg; J Dichgans; U Bogdahn; M Weller
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

5.  Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report.

Authors:  Thomas Krampulz; Volkmar H Hans; Falk Oppel; Uwe Dietrich; Maximilian J A Puchner
Journal:  J Neurooncol       Date:  2006-03-10       Impact factor: 4.130

6.  Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397).

Authors:  Paul L Moots; Anne O'Neill; Harold Londer; Minesh Mehta; Deborah T Blumenthal; Geoffrey R Barger; Margaret L Grunnet; Stuart Grossman; Mark R Gilbert; David Schiff
Journal:  Am J Clin Oncol       Date:  2018-06       Impact factor: 2.339

Review 7.  Childhood medulloblastoma: current status of biology and treatment.

Authors:  Laura J Klesse; Daniel C Bowers
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

8.  Patterns of care in adult medulloblastoma: results of an international online survey.

Authors:  Rasha Cosman; Christopher S B Brown; Kevin C DeBraganca; Mustafa Khasraw
Journal:  J Neurooncol       Date:  2014-07-16       Impact factor: 4.130

9.  Analysis of microsatellite instability in medulloblastoma.

Authors:  Marta Viana-Pereira; Inês Almeida; Sónia Sousa; Bethânia Mahler-Araújo; Raquel Seruca; José Pimentel; Rui Manuel Reis
Journal:  Neuro Oncol       Date:  2009-01-29       Impact factor: 12.300

Review 10.  Brain tumors across the age spectrum: biology, therapy, and late effects.

Authors:  Thomas E Merchant; Ian F Pollack; Jay S Loeffler
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.